公开(公告)号：US20190338026A1

公开(公告)日：2019-11-07

申请号：US16475223

申请日：2018-01-02

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： X. Charlene LIAO ,  Qiang LIU ,  Zhiqiang AN ,  Ningyan ZHANG ,  Xun GUI ,  Chengcheng ZHANG ,  Mi DENG ,  Jingjing XIE

IPC: C07K16/28 ,  C12N5/12 ,  C12N15/85

Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

公开(公告)号：US20230068663A1

公开(公告)日：2023-03-02

申请号：US17759800

申请日：2021-01-28

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

Inventor： Zhiqiang AN ,  Ningyan ZHANG ,  Zhiqiang KU ,  Chengcheng ZHANG ,  Xiaoye XU ,  Heyu CHEN ,  JingJing XIE ,  Maria Jose COSTA ,  An SONG ,  X. Charlene LIAO

IPC: C07K16/28 ,  A61K45/06 ,  A61K47/68 ,  A61P35/02 ,  A61K39/395 ,  G01N33/574

Abstract: Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

公开(公告)号：US20210371518A1

公开(公告)日：2021-12-02

申请号：US17275838

申请日：2019-09-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

Inventor： Zhiqiang AN ,  Chengcheng ZHANG ,  Ningyan ZHANG ,  Xun GUI ,  Mi DENG ,  Tao HUANG ,  Qiang LIU ,  X. Charlene LIAO

IPC: C07K16/28 ,  A61P35/02 ,  A61K45/06 ,  A61K39/395 ,  A61K47/68 ,  A61K51/10 ,  G01N33/574 ,  A61K47/69

Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.